Trials / Completed
CompletedNCT07337252
Risk Factors for Treatment Failure in Women With Detrusor Overactivity Receiving Combined Pharmacotherapy
Risk Factors for the Failure of Combined Pharmacotherapy in Women With Refractory Detrusor Overactivity
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 61 (actual)
- Sponsor
- Mackay Memorial Hospital · Academic / Other
- Sex
- Female
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study evaluated the outcomes of women with detrusor overactivity treated with combined pharmacotherapy to identify risk factors for treatment failure.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Combined pharmacotherapy | Combined pharmacotherapy with oral solifenacin 5 mg and mirabegron 25 mg once daily. |
Timeline
- Start date
- 2022-06-01
- Primary completion
- 2024-06-30
- Completion
- 2024-08-31
- First posted
- 2026-01-13
- Last updated
- 2026-01-13
Locations
1 site across 1 country: Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07337252. Inclusion in this directory is not an endorsement.